SCHEMBL3408797

SCHEMBL3408797

O=C(NCCSc1ccccc1)c1cncc(Br)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 1.00
NPC1 O15118 7/20 1.00
RAB9A P51151 7/20 1.00
ALDH1A1 P00352 7/20 1.00
CASP3 P42574 2/20 0.67
NFKB1 P19838 2/20 0.67
NFKB2 Q00653 2/20 0.67
RELA Q04206 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
SENP8 Q96LD8 1/20 0.67
SENP7 Q9BQF6 1/20 0.67
SENP6 Q9GZR1 1/20 0.67
PKM P14618 1/20 0.64
POLB P06746 1/20 0.64
RECQL P46063 1/20 0.63
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
HPGD P15428 1/20 0.56
CYP2C19 P33261 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29858769 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9AALDH1A1CASP3
SCHEMBL14096624 0.83 NPC1 (0.71) SMN1; SMN2NPC1RAB9AALDH1A1CASP3
SCHEMBL19688299 0.77 POLB (0.72) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL1558714 0.77 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9AALDH1A1CASP3
SCHEMBL15228268 0.76 PKM (0.67) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL31533961 0.76 PKM (0.67) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL6361404 0.76 PKM (0.71) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL8613499 0.75 RAB9A (0.79) SMN1; SMN2NPC1RAB9AALDH1A1CASP3
SCHEMBL31313370 0.75 NPC1 (0.67) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1
SCHEMBL26426186 0.75 NPC1 (0.67) SMN1; SMN2NPC1RAB9AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators NIH-DEITR 2017-07-06 US claimed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US claimed
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-04 US claimed
WO-2014145205-A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2014-09-18 WO claimed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 EP claimed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US claimed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO claimed
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS MASSACHUSETTS EYE AND EAR INFIRMARY 2025-03-27 US disclosed
US-12239651-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2025-03-04 US disclosed
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-12-03 US disclosed
US-20240299432-A1 TREATMENT OF HEARING LOSS MASSACHUSETTS EYE AND EAR INFIRMARY 2024-09-12 US disclosed
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-07-23 US disclosed
US-11963968-B2 Treatment of hearing loss MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2024-04-23 US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 US disclosed
US-20110183984-A1 SMALL MOLECULE INHIBITORS OF LCK SH2 DOMAIN BINDING UNIVERSITY OF MARYLAND, BALTIMORE 2011-07-28 US disclosed
US-20110183984-A1 SMALL MOLECULE INHIBITORS OF LCK SH2 DOMAIN BINDING UNIVERSITY OF MARYLAND, BALTIMORE 2011-07-28 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299432-A1 TREATMENT OF HEARING LOSS HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885
US-20110183984-A1 SMALL MOLECULE INHIBITORS OF LCK SH2 DOMAIN BINDING LCK, ZAP70, FYN SMN1; SMN2 3674/4885NPC1 4791/4885RAB9A 2432/4885
US-12043653-B2 Efficient delivery of therapeutic molecules to cells of the inner ear HES1, NOTCH1, NOTCH2 SMN1; SMN2 4645/4885NPC1 1630/4885RAB9A 2455/4885
US-20170189477-A1 Methods and Compositions of P27KIP1 Transcriptional Modulators WNT1, CTNNB1, CTNNBL1 SMN1; SMN2 4085/4885NPC1 1011/4885RAB9A 4314/4885
US-12156899-B2 Methods and compositions for regenerating hair cells and/or supporting cells HES1, NOTCH1, NOTCH4 SMN1; SMN2 4643/4885NPC1 1656/4885RAB9A 3020/4885
US-20250099539-A1 METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS HES1, NOTCH1, NOTCH4 SMN1; SMN2 4643/4885NPC1 1656/4885RAB9A 3020/4885
US-20160030445-A1 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS WNT1, CTNNB1, CTNNBL1 SMN1; SMN2 4190/4885NPC1 966/4885RAB9A 4168/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP SMN1; SMN2 2179/4885NPC1 1018/4885RAB9A 3293/4885
US-12239651-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885
US-11963968-B2 Treatment of hearing loss HES1, NOTCH1, NOTCH4 SMN1; SMN2 3919/4885NPC1 1607/4885RAB9A 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.